Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data

Liver International

Volumn 35, Issue 3, 2015, Pages 860-869

  Kim, Hae Rim ^a   Yim, Hyung Joon ^a   Kang, Seonghee ^a   Suh, Sang Jun ^a   Kim, Seung Young ^a   Hyun, Jong Jin ^a   Koo, Ja Seol ^a   Kim, Ji Hoon ^a   Seo, Yeon Seok ^a   Yeon, Jong Eun ^a   Lee, Sang Woo ^a   Byun, Kwan Soo ^a   Um, Soon Ho ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Cirrhosis; Entecavir; Hepatitis B; Telbivudine

Indexed keywords

CREATINE KINASE; ENTECAVIR; TELBIVUDINE; VIRUS DNA; ANTIVIRUS AGENT; GUANINE; HEPATITIS B(E) ANTIGEN; THYMIDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHILD TURCOTTE PUGH SCORE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; SEROLOGY; TREATMENT RESPONSE; VIRUS INHIBITION; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; THYMIDINE; VIRAL LOAD;

EID: 84940264044     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12605     Document Type: Article

References (24)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.
2. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996; 276: 906-8.
3. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol 2009; 15(Suppl 6): S13-24.
4. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
5. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
6. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
7. Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 2007; 29: 2635-53.
8. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
9. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
10. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-82.
11. Division of AIDS. Table for grading severity of adult and pediatric adverse events. UC Davis Web site (www.ucdmc.ucdavis.edu/clinicaltrials/studytools/documents//daids); 2004.
12. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
13. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
14. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745-54.
15. Shamliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009; 150: 111-24.
16. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-6.
17. Han Z, Shi Y, Zhu J, et al. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. J Viral Hepat 2013; 20(Suppl. 1): 58-64.
18. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-34.
19. Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-43.
20. Gane EJ, Deray G, Liaw YF, et al. Telbivudine Improves Renal Function in Patients with Chronic Hepatitis B. Gastroenterology 2014; 146: e5.
21. Yim HJ, Hwang SG. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol 2013; 19: 195-209.
22. Hann HW. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Gastroenterology 2009; 136: 486-95.
23. Piratvisuth T, Komolmit P, Tanwandee T, et al. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS ONE 2013; 8: e54279.
24. He J, Bowen JM, Xie F, Goeree R. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. Value Health 2012; 15: 894-906.